Question · Q1 2024
Shinya Tsuzuki of Mizuho Securities asked for confirmation of the rising number of COVID patients since the April-June period and requested an update on the manufacturing enhancement status for the COVID vaccine.
Answer
Takeki Uehara, Corporate Officer, confirmed a gradual increase in infections and sales, driven by Xocova's strong market share. Koji Hanasaki, Executive Officer, detailed the vaccine manufacturing plan, with the first lot at the Akita plant and mass production at the Unigen plant in Gifu, noting that scale-up trials and process improvements are currently underway.